2:13 PM
Sep 12, 2018
 |  BC Extra  |  Preclinical News

Genentech develops antibiotic against multidrug resistant Gram-negatives

Genentech Inc. researchers have developed arylomycin derivatives with potent activity against Gram-negative bacteria, including multidrug resistant (MDR) strains. The small molecule could represent a notable step forward against Gram-negative bacteria, for which no new class of antibiotics has been approved in over 50 years.

Arylomycins are macrocyclic lipopeptides that target bacterial signal peptidase I (bacterial lepB) produced by both Gram-positive and Gram-negative bacteria; however, researchers have focused on developing arylomycins targeting...

Read the full 332 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >